Get the Stockscreener App
4.06
3.79%
-0.16
After Hours:
4.06
Macrogenics Inc stock is traded at $4.06, with a volume of 638.42K.
It is down -3.79% in the last 24 hours and down -9.58% over the past month.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
See More
Previous Close:
$4.22
Open:
$4.21
24h Volume:
638.42K
Relative Volume:
0.64
Market Cap:
$258.40M
Revenue:
$157.08M
Net Income/Loss:
$-70.36M
P/E Ratio:
-3.6524
EPS:
-1.1116
Net Cash Flow:
$-71.69M
1W Performance:
-0.49%
1M Performance:
-9.58%
6M Performance:
+138.82%
1Y Performance:
+156.96%
1-Day Range:
$4.005
$4.30
1-Week Range:
$3.785
$4.3091
52-Week Range:
$1.29
$5.08
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
4.06 | 268.58M | 157.08M | -70.36M | -71.69M | -1.1116 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Upgrade | B. Riley Securities | Neutral → Buy |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
MGNX Maintained by B. Riley Securities -- Price Target Raised to $11.00 - GuruFocus
B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating - marketscreener.com
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst? - Yahoo Finance
MacroGenics 2026: Revenue $32.83M, EPS $0.31— 10-Q Summary - TradingView
MacroGenics (MGNX) gains $86M on CDMO sale as royalties and milestones rise - Stock Titan
Armistice Capital (MGNX) discloses 5.0M-share MacroGenics position in 13G/A - Stock Titan
MacroGenics Inc earnings missed by $1.02, revenue fell short of estimates - Investing.com Nigeria
MacroGenics (NASDAQ:MGNX) Posts Earnings Results, Beats Estimates By $0.39 EPS - MarketBeat
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
MacroGenics Q2 adj. EPS $(0.27) misses $(0.13) estimate; sales miss - scanx.trade
MacroGenics: Q2 Earnings Snapshot - Yahoo Finance
MacroGenics : Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position Announced sale of manufacturing operations ( July 2026) for $122.5 million and transition to fully outsourced model with leaner - marketscreener.com
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position - manilatimes.net
Gilead exercises option for MacroGenics pre-clinical bispecific program - The Pharma Letter
MacroGenics, Inc. $MGNX Shares Bought by Wasatch Advisors LP - MarketBeat
Gilead exercises option on MacroGenics bispecific program By Investing.com - Investing.com UK
MacroGenics stock rises on $10M Gilead option exercise By Investing.com - Investing.com South Africa
MacroGenics stock rises on $10M Gilead option exercise - Investing.com
Gilead exercises option on MacroGenics bispecific program - Investing.com
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program - manilatimes.net
MacroGenics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
MacroGenics (MGNX) Projected to Release Earnings on Thursday - MarketBeat
MGNX (NASDAQ: MGNX) holder files to sell 20,166 common shares under Rule 144 - stocktitan.net
Bank of America (NYSE: BAC) reports 4.0% beneficial stake in MacroGenics (MGNX) - Stock Titan
MacroGenics Inc (MGNX) Institutional Confidence - TradingKey
BlackRock (MGNX holder) discloses 7.1% MacroGenics stake in Schedule 13G filing - Stock Titan
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important (MGNX) - Seeking Alpha
Citizens reiterates MacroGenics stock rating ahead of ESMO data - Investing.com
Citizens reiterates MacroGenics stock rating ahead of ESMO data By Investing.com - Investing.com Canada
MacroGenics Inc (MGNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MacroGenics, Inc. Revenue Breakdown – NASDAQ:MGNX - TradingView
MGNX|MacroGenics Inc|Price:3.700|Chg%:-0.310 - TradingKey
MacroGenics Inc (MGNX) Cash Flow - TradingKey
MacroGenics, Inc. Revenue Breakdown – DUS:M55 - TradingView
TradingKey - TradingKey
MacroGenics slips on trial data for lead asset (MGNX:NASDAQ) - Seeking Alpha
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026 - manilatimes.net
MacroGenics’ MGC026 meets Phase 1 trial milestone in SCCHN - Investing.com
MacroGenics (MGNX) Advances Phase 1 Study of MGC026 - GuruFocus
MacroGenics’ MGC026 meets trial threshold in head and neck cancer By Investing.com - Investing.com Nigeria
MacroGenics Advances MGC026 in Phase 1 Oncology Trial - TipRanks
MacroGenics’ MGC026 meets trial threshold in head and neck cancer - Investing.com
Entera Bio Leads Our Top 3 Penny Stocks To Consider - Sahm
MGNX stock holds focus as MacroGenics plans and pipeline metrics matter - Ad-hoc-news.de
MacroGenics (MGNX): Millennium group discloses 3.7% beneficial stake in amended 13G - Stock Titan
MacroGenics stock gains after FDA priority review as revenue rises and cash runway extends - Ad-hoc-news.de
MacroGenics Inc (NASDAQ: MGNX) Share Price, MGNX Stock News, MGNX Share Price & Updates - Kalkine
[144] MACROGENICS INC SEC Filing - Stock Titan
Form 144 MACROGENICS For: 13 July By Investing.com - Investing.com Nigeria
MacroGenics (MGNX) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
MGNX Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Pipeline DevelopmentOperating Margin Analysis - dars.gov.et
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.80%
1.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):